NCT02286726View on ClinicalTrials.gov

CPX-351 in Treating Patients With Newly Diagnosed, High-Risk Acute Myeloid Leukemia

PHASE2CompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

May 4, 2015

Primary Completion Date

January 22, 2020

Study Completion Date

January 22, 2020

Conditions
Acute Myeloid LeukemiaAcute Myeloid Leukemia Arising From Previous Myelodysplastic SyndromeSecondary Acute Myeloid Leukemia
Interventions
OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Liposome-encapsulated Daunorubicin-Cytarabine

Given IV

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER

NCT02286726 - CPX-351 in Treating Patients With Newly Diagnosed, High-Risk Acute Myeloid Leukemia | Biotech Hunter | Biotech Hunter